Aclaris Therapeutics, Inc. Business Finance Contracts & Agreements
28 Contracts & Agreements
- Assignment Agreements (3 contracts)
- Investor Rights Agreements (1)
- Loan Agreements (2)
- Purchase Agreements (6)
- Registration Rights Agreements (3)
- Stock Agreements (6)
- Underwriting Agreements (6)
- Warrant Agreements (1)
- Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement used in connection with the Aclaris Therapeutics, Inc. 2024 Inducement Plan (Filed With SEC on November 18, 2024)
- Form of Stock Option Grant Notice and Stock Option Agreement used in connection with the Aclaris Therapeutics, Inc. 2024 Inducement Plan (Filed With SEC on November 18, 2024)
- Form of Registration Rights Agreement, dated November 18, 2024, by and between the Company and the investors named therein (Filed With SEC on November 18, 2024)
- Form of Securities Purchase Agreement, dated November 18, 2024, by and between the Company and the investors named therein (Filed With SEC on November 18, 2024)
- Royalty Purchase Agreement, effective as of July 16, 2024, by and between the Registrant and OCM IP Healthcare Portfolio LP (Filed With SEC on August 7, 2024)
- Underwriting Agreement by and among Aclaris Therapeutics, Inc., Jefferies LLC, SVB Leerink LLC and Piper Sandler & Co., dated June 9, 2021 (Filed With SEC on June 11, 2021)
- Underwriting Agreement by and among Aclaris Therapeutics, Inc., Cantor Fitzgerald & Co. and William Blair & Company, L.L.C., dated January 20, 2021 (Filed With SEC on January 22, 2021)
- Registration Rights Agreement, dated as of August 13, 2020, by and between the Company and Lincoln Park (Filed With SEC on August 13, 2020)
- Purchase Agreement, dated as of August 13, 2020, by and between the Company and Lincoln Park (Filed With SEC on August 13, 2020)
- Warrant to Purchase Stock, issued to Silicon Valley Bank, dated as of March 30, 2020 (Filed With SEC on March 31, 2020)
- Loan and Security Agreement, by and among the Company, Confluence Discovery Technologies, Inc. and Silicon Valley Bank, dated as of March 30, 2020 (Filed With SEC on March 31, 2020)
- Asset Purchase Agreement, by and between the Company and EPI Health, LLC, dated as of October 10, 2019 (Filed With SEC on October 11, 2019)
- Loan and Security Agreement, dated as of October 15, 2018, by and among Oxford Finance LLC, the lenders party thereto, the Registrant, Confluence Discovery Technologies, Inc. and... (Filed With SEC on March 18, 2019)
- Asset Purchase Agreement, by and between the Company and Allergan Sales, LLC, dated as of October 15, 2018, as amended on November 30, 2018 (Filed With SEC on December 3, 2018)
- Underwriting Agreement by and among Aclaris Therapeutics, Inc., Leerink Partners LLC and Evercore Group L.L.C., dated October 17, 2018 (Filed With SEC on October 18, 2018)
- 3,260,000 Aclaris Therapeutics, Inc. Common Shares UNDERWRITING AGREEMENT (Filed With SEC on August 11, 2017)
- Aclaris Therapeutics, Inc. Restricted Stock Unit Grant Notice (2017 Inducement Plan) (Filed With SEC on August 1, 2017)
- Aclaris Therapeutics, Inc. 2017 Inducement Plan Stock Option Grant Notice (Filed With SEC on August 1, 2017)
- 4,000,000 Aclaris Therapeutics, Inc. Common Shares UNDERWRITING AGREEMENT (Filed With SEC on November 18, 2016)
- ACLARIS THERAPEUTICS, INC. $75,000,000 COMMON STOCK SALES AGREEMENT (Filed With SEC on November 2, 2016)
- AMENDMENT TO ASSIGNMENT AGREEMENT (Filed With SEC on June 17, 2016)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on June 2, 2016)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on June 2, 2016)
- STOCK PURCHASE AGREEMENT (Filed With SEC on May 11, 2016)
- ASSIGNMENT AGREEMENT (Filed With SEC on September 25, 2015)
- [ ] Aclaris Therapeutics, Inc. Common Shares UNDERWRITING AGREEMENT (Filed With SEC on September 25, 2015)
- ACLARIS THERAPEUTICS, INC. SECOND AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT (Filed With SEC on September 4, 2015)
- ASSIGNMENT AGREEMENT (Filed With SEC on August 17, 2015)
